Novo Nordisk A/S
Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data
Aykut Karahan | Istock | Getty Images Shares of Structure Therapeutics rose more than 30% on Friday after the biotech startup’s experimental obesity pill succeeded in a small early-stage trial. The once-daily drug helped overweight or obese participants reduce up to 10 pounds of weight on average after four weeks of treatment, according to a […]
Read More
Ad spending for obesity, diabetes drugs is soaring this year, as drugmakers shell out nearly $500 million
A view of a plastic model of a stomach during an interview with Doctor Thomas Horbach, specialist in surgery, visceral surgery and nutritional medicine on Novo Nordisk, which will start selling its hugely popular obesity drug Wegovy in Germany later this month, in Munich, Germany, July 17, 2023. Christine Uyanik | Reuters Drugmakers spent nearly […]
Read More
Will weight loss drugs lead to less food consumption? Here’s what Walmart is saying
More than 40% of adults in the U.S. are obese. That’s a big number, which makes the group a force to be reckoned with if their habits start to change suddenly. That’s why we’ve seen so many Wall Street analysts exploring the potential fallout from new weight loss medications like Novo Nordisk’s Wegovy and Ozempic […]
Read More
Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters U.S. health care providers wrote more than nine million prescriptions for Ozempic, Wegovy and similar diabetes and obesity drugs during […]
Read More
Here are the risks to alcohol and food stocks from Ozempic-like weight loss drugs
The rise of new anti-obesity medications could result in less alcohol consumption, impacting Club name Constellation Brands (STZ). The risk already seems to be playing out in food stocks with exposure to snacks and junk food. However, if necessary, the Mexican beer powerhouse behind Corona, Modelo and Pacifico could take action to mitigate any demand […]
Read More
Eli Lilly sues clinics allegedly selling knockoff versions of Mounjaro diabetes drug
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, March 29, 2023. George Frey | Reuters Eli Lilly on Tuesday sued 10 medical spas, wellness clinics and compounding pharmacies across the U.S. for allegedly selling cheaper, unauthorized […]
Read More
Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
As new weight loss medications garnered buzz last year, analysts’ forecasts signaled these drugs would be blockbusters, with some of the highest estimates calling for peak sales of at least $100 billion. In recent days, the expectations are moving higher still. The initial projections were made before Wall Street saw the results of Novo Nordisk’s […]
Read More
Wager in opposition to America’s enjoy for junk food stuff? Morgan Stanley sees hard periods forward for snack stocks like Hostess
J.M. Smucker ‘s prepare to obtain Twinkies -maker Hostess Models is a risky shift, if Morgan Stanley’s most current investigate is appropriate. The company revisited its August call that a new course of body weight loss medicines would hamper expansion at some foodstuff and beverage firms . This time it backed up its thesis with […]
Read More
Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors – here’s what we know
An Ozempic (semaglutide) injection pen is seen on a kitchen table in Riga, Latvia on 06 August, 2023. Jaap Arriens | Nurphoto | Getty Images Heather Le Biller shed 9 pounds within the first week of taking Novo Nordisk‘s blockbuster diabetes drug Ozempic – and then even more as she continued treatment. Le Biller, a […]
Read More
Big pharma’s blockbuster obesity drug battle is just getting started, and it’s headed for $100 billion
Ozempic drug to treat diabetes. Courtesy: Ozempic In their most recent earnings reports, Novo Nordisk and Eli Lilly proved why they are the undisputed heavyweights in the prizefight for control of the rapidly growing weight-loss medications market. Beyond staggering sales figures for Novo’s Ozempic and Wegovy and Lilly’s Mounjaro, news of a study showing Wegovy […]
Read More